Cytogenetics News and Research RSS Feed - Cytogenetics News and Research

Cytogenetics is a field of study that deals with chromosomes and related abnormalities. Chromosome analysis is also known as karyotyping and involves the pairing of homologous chromosomes.
Updated guidelines for breast cancer increase number of patients who test HER2-positive

Updated guidelines for breast cancer increase number of patients who test HER2-positive

Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology. [More]
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year. [More]
Four miRNAs may hold vital clue to disease progression in gliobastoma

Four miRNAs may hold vital clue to disease progression in gliobastoma

Scientists at the Helmholtz Zentrum München and the Ludwig Maximilians University of Munich have developed a new method of predicting disease progression in gliobastoma patients who have undergone standard treatment. [More]
OGT launches Cytocell FISH probes for glial tumours

OGT launches Cytocell FISH probes for glial tumours

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® 1p36/1q25 and 19q13/19p13 Deletion Probe Kit*, a cost-effective fluorescence in situ hybridisation (FISH) kit for the reliable investigation of glial tumours. [More]
Diversigen, Baylor Miraca to provide customers access to targeted genomics and metabolomics services

Diversigen, Baylor Miraca to provide customers access to targeted genomics and metabolomics services

Diversigen, Inc., the leading provider of comprehensive microbiome analysis services, today announced a strategic partnership with Baylor Miraca Genetics Laboratories, a global leader in genetic testing, to provide their customers access to a broad range of targeted genomics and metabolomics services. [More]
NeoGenomics acquires Clarient and Clarient Diagnostic Services

NeoGenomics acquires Clarient and Clarient Diagnostic Services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has completed the acquisition of Clarient, Inc. and its wholly-owned subsidiary Clarient Diagnostic Services, Inc. Clarient, a provider of comprehensive cancer diagnostic testing to hospitals, physicians and the pharmaceutical industry, was a unit of GE Healthcare's Life Sciences business. [More]
Researchers identify new gene that helps maintain chromosome number in cells

Researchers identify new gene that helps maintain chromosome number in cells

Molecular biologists at UT Southwestern Medical Center have identified a gene called NORAD that helps maintain the proper number of chromosomes in cells, and that when inactivated, causes the number of chromosomes in a cell to become unstable, a key feature of cancer cells. [More]
Mitochondrial variation and viable pregnancy: an interview with Dr Elpida Fragouli

Mitochondrial variation and viable pregnancy: an interview with Dr Elpida Fragouli

Embryos require adequate amounts of energy so that they can successfully progress through each of their cell divisions. [More]
NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its liquid biopsy testing menu to include two new tests, a NeoLAB Solid Tumor Monitor and a NeoLAB BTK Inhibitor Acquired Resistance test. [More]
Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma. [More]
Age doesn't matter when considering HCT for patients with MDS, study reveals

Age doesn't matter when considering HCT for patients with MDS, study reveals

Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable to patients aged 55 to 64. [More]
Research reveals genetic variants linked to treatment-related complications in children with blood diseases

Research reveals genetic variants linked to treatment-related complications in children with blood diseases

Research to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition reveals genetic variants that are associated with disease severity and treatment-related complications in children with blood diseases. [More]
Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill. [More]
Baylor Miraca Genetics Laboratories licenses SNP probe technology from OGT

Baylor Miraca Genetics Laboratories licenses SNP probe technology from OGT

Oxford Gene Technology (OGT), The Molecular Genetics Company, has entered into a deal with Baylor Miraca Genetics Laboratories (BMGL), licensing the use of OGT’s proprietary single nucleotide polymorphism (SNP) array probe technology. [More]
Researchers develop multiplexed screening approach to study cancer development in mice

Researchers develop multiplexed screening approach to study cancer development in mice

In a novel use of the CRISPR/Cas9 system, which can be deployed to switch genes off, researchers from Germany, the UK and Spain have developed a multiplexed screening approach to study and model cancer development in mice. The scientists mutated genes in the adult mouse liver uncovering their cancer-causing roles and determining which combinations of genes cooperate to cause liver cancer. [More]
Proposed thin-plate model sheds light on structural basis of chromosomal aberrations in cancer cells

Proposed thin-plate model sheds light on structural basis of chromosomal aberrations in cancer cells

During cell division, each metaphase chromosome contains a single enormously long DNA molecule that is associated with histone proteins and forms a long chromatin filament with many nucleosomes. [More]
CUMC's Laboratory of Personalized Genomic Medicine granted approval for Columbia Combined Cancer Panel

CUMC's Laboratory of Personalized Genomic Medicine granted approval for Columbia Combined Cancer Panel

The Laboratory of Personalized Genomic Medicine at Columbia University Medical Center has been granted full approval by the New York State Department of Health for the Columbia Combined Cancer Panel, (CCCP). This panel queries 467 cancer-related genes and was designed in collaboration with Columbia University Medical Center oncologists. [More]
NeoGenomics introduces new NeoSITE Cervical FISH assay

NeoGenomics introduces new NeoSITE Cervical FISH assay

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its comprehensive FISH (Fluorescence In Situ Hybridization) testing menu to include a new NeoSITE Cervical assay to provide additional diagnostic information on abnormal Pap smears. [More]
Persistent leukemia-associated genetic mutations linked to increased risk of relapse, reduced overall survival

Persistent leukemia-associated genetic mutations linked to increased risk of relapse, reduced overall survival

In preliminary research, the detection of persistent leukemia-associated genetic mutations in at least 5 percent of bone marrow cells in day 30 remission samples among adult patients with acute myeloid leukemia was associated with an increased risk of relapse and reduced overall survival, according to a study in the August 25 issue of JAMA. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
Advertisement
Advertisement